Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:42 PM
Ignite Modification Date:
2025-12-24 @ 7:42 PM
NCT ID:
NCT05073003
Eligibility Criteria:
Inclusion Criteria:
All participants:
* Participants and/or participants' parent(s)/legally acceptable representative(s) LAR(s), who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits).
* Written or witnessed/thumb printed informed consent obtained from the participant/parent(s)/LAR(s) of the participant prior to performance of any study specific procedure.
* Healthy participants as established by medical history, clinical examination, and laboratory assessment.
* Participants satisfying all screening requirements.
* Participants seronegative for hepatitis B, and hepatitis C.
* Participants negative for human leukocyte antigen B27 (HLA-B27).
Adults 18 to 50 years of age:
* A male or female between, and including, 18 and 50 years of age at the time of the first study intervention administration.
* Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause.
* Female participants of childbearing potential may be enrolled in the study, if the participant:
\- has practiced adequate contraception for 1 month prior to study intervention administration, and
\- has a negative pregnancy test on the day of study intervention administration, and
* has agreed to continue adequate contraception during the entire treatment period and for 1 month after completion of the study intervention administration series.
* Participants seronegative for human immunodeficiency virus (HIV).
Children 24 to 59 months of age:
* A male or female between, and including, 24 and 59 months of age at the time of first vaccination.
* Normal nutritional Z score (-2 standard deviation or greater).
* Previously completed routine childhood vaccinations to the best knowledge of the participant's parent(s)/LAR(s).
* Born after gestation period of ≥37 weeks.
* Participants seronegative for HIV.
Infants 9 months of age:
* A male or female 9 months of age at the time of first vaccination.
* Normal nutritional Z score (-2 standard deviations or greater).
* Previously completed routine childhood vaccinations to the best knowledge of the participant's parent(s)/LAR(s).
* Born after a gestation period of ≥37 weeks.
* Participants negative for HIV as confirmed by deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) testing.
Exclusion Criteria:
All participants:
* Known exposure to Shigella during lifetime of the participant as confirmed during interview with the participant or documented by patient records (e.g., history of microbiologically-confirmed Shigella infection), recent travel\* (within 2 years) to a country where Shigella or other enteric infections are endemic, or recent occupation\* (within 3 years) involving Shigella species.
\*Exclusion due to travel or occupation is applicable only to Adults 18 to 50 years of age in Europe (Stage 1).
* Progressive, unstable or uncontrolled clinical conditions.
* History (known or suspected) of any reaction or hypersensitivity likely to be exacerbated by any component of the study vaccine.
* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
* Hypersensitivity, including allergy, to medicinal products or medical equipment whose use is foreseen in this study.
* Clinical conditions representing a contraindication to IM vaccination and blood draws.
* Any behavioural or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the participant's ability to participate in the study.
* Acute disease and/or fever (defined as temperature ≥38.0°C) at the time of enrolment\*.
* The participant can still be enrolled into the study at a time when the acute disease and/or fever has resolved.
* Any clinically significant haematological and/or biochemical laboratory abnormality.
* Confirmed positive COVID-19 test during the period starting 30 days before the first administration of study vaccines (Day -30 to Day 1).
* Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.
* Administration of long-acting immune-modifying drugs at any time during the study period (e.g. infliximab).
* Prior receipt of an experimental Shigella vaccine or live Shigella challenge.
* Use of any investigational or non-registered product (drug, vaccine or medical device)\* other than the study vaccine during the period starting 30 days before the first dose of study intervention (Day -30 to Day 1), or planned use during the study period.
\*Use of herbs and traditional treatments is not considered an exclusion criterion
* A vaccine not foreseen\* by the Study Protocol administered during the period starting at -21 days before the first dose (-28 days in the case of live vaccines) and ending after the last dose of study intervention administration\*\*.
\*Vaccines allowed by the Protocol include flu and COVID-19 vaccines in all participants and EPI vaccines in children and infants.
\*\*In case of emergency mass vaccination, the time period above can be reduced.
* Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug or invasive medical device).
* Any study personnel or immediate dependents, family, or household member.
Adults 18 to 50 years of age:
* Acute or chronic illness, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.
* Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 3 months prior to the first vaccine study intervention. For corticosteroids, this will mean prednisone equivalent ≥20 mg/day for adult participants. Inhaled and topical steroids are allowed.
* Pregnant or lactating female.
* Female planning to become pregnant or planning to discontinue contraceptive precautions.
* History of or current chronic alcohol consumption and/or drug abuse.
Adults 18 to 50 years of age and Children 24 to 59 months age:
• Administration of immunoglobulins and/or any blood products or plasma derivatives, or bone marrow transplantation, during the period starting 3 months before the first dose of study vaccine or planned administration during the study period.
Children 24 to 59 months of age and infants 9 months of age:
* Acute or chronic clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.
* Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 3 months prior to the first vaccine dose. For corticosteroids, this will mean prednisone ≥0.5 mg/kg/day or 20 mg/day whichever is the maximum dose for paediatric participants. Inhaled and topical steroids are allowed.
* Child in care.
Infants 9 months of age:
• Administration of immunoglobulins and/or any blood products or plasma derivatives, or bone marrow transplantation, from birth or planned administration during the study period.
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
9 Months
Maximum Age:
50 Years
Study:
NCT05073003
Study Brief:
Protocol Section:
NCT05073003